Company Overview and News

7
Kraft Heinz Is Struggling

11h seekingalpha
The entire packaged goods sector has been struggling of late. Kraft Heinz has been no exception to the rule.
BRK.A UL CPB KHC

18
More Changes to the Pharmacy Industry Coming as DOJ Approves Cigna-Express Scripts Deal

18h biospace
In March, U.S. insurer CIGNA Corporation announced it was acquiring pharmacy benefits manager Express Scripts for approximately $52 billion. On Monday, the Department of Justice (DOJ) approved the merger.
BRK.A NYTAB CI CVS

4
Buffett And Munger Recommend Investing With The Cannibals

19h seekingalpha
Investors should focus on a company with management that only executes buybacks when the company is trading at a discount to intrinsic value.
BRK.A AZO AAPL

3
LinkedIn says these are the 25 most attractive startups to work for in India

23h moneycontrol
The world’s largest professional network, LinkedIn, on Tuesday announced the 2018 LinkedIn Top Startups List for India, revealing the 25 most-wanted startups by professionals.
BRK.A 532454 DB 500477 BHRQY BHARTIARTL AKLS AKLD ASHOKLEY

20
Cigna deal gets antitrust nod, positive sign for CVS/Aetna

2018-09-17 reuters
(Reuters) - Health insurer Cigna Corp’s (CI.N) $52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

20
Cigna-Express Scripts deal gets US antitrust approval

2018-09-17 channelnewsasia
Health insurer Cigna Corp's US$52 billion acquisition of pharmacy benefits manager Express Scripts Holding Co has passed U.S. antitrust scrutiny, the companies said on Monday, allowing them to proceed with a combination they say will lead to lower costs by better coordinating pharmacy and medical benefits.
ATHTF BRK.A TWX ANTM CI CVS TWC HUM AET ANTX

10
The two reasons billionaires keep snapping up print media companies

2018-09-17 marketwatch
On Sunday, Salesforce.com co-founder Marc Benioff and his wife, Lynne Benioff, joined a growing crowd of deep-pocketed individuals buying up print media assets.
BRK.A MDPEB MDP TIME

5
Cannabis: The New Consumer Staple

2018-09-17 seekingalpha - 1
Canadian legal recreational cannabis sales are starting on October 17, 2018, while the US Congress is making significant advances toward legalization.
BRK.A WEED APHQF CNTTF CGC

17
Crashes And Cash - Weekly Blog # 542

2018-09-17 seekingalpha
Was the Financial Times headline: "Traders lost bet blows hole in post-crisis safety net" the announcement of the Arch Duke's murder? The loss results from a more than $160 million default on margined futures trades at the NASDAQ (*) clearing house facility. Morgan Stanley(*) (NYSE:MS), UBS(*) and Norway's State Oil Company will have less than 48 hours to cover their defaulting counterparty. We think they will, but the size of their risks may give the professional market cause for concern as to the general risk in the marketplace.
BRK.A TRI MS BX

3
Private equity/venture capital firms still keen on financial services deals: EY

2018-09-17 livemint
Mumbai: Non-performing assets (NPAs) and financial frauds in the Indian banking sector have not deterred private equity and venture capital firms from investing in financial services, a report by EY and Indian Private Equity and Venture Capital Association shows. The Indian financial services sector, in fact, witnessed $4 billion of investments in the first half of 2018, the highest ever half-yearly investment, following the recent investment by Warren Buffett’s Berkshire Hathaway in Paytm.
BRK.A HGRL

3
Crunch time: could Trump and China test investor faith in Apple

2018-09-16 theage.com.au
The largest Australian shareholder in Apple remains bullish on the world's most valuable company - but is concerned it could be collateral damage in a trade war between the United States and China.
BRK.A MFG

3
Crunch time: could Trump and China test investor faith in Apple

2018-09-16 smh.com.au
The largest Australian shareholder in Apple remains bullish on the world's most valuable company - but is concerned it could be collateral damage in a trade war between the United States and China.
BRK.A MFG

3
BookWatch: India can teach the U.S. how to slash health-care costs by 40% — without rationing care

2018-09-15 marketwatch
Vijay Govindarajan, a Dartmouth College professor who focuses on innovation, and Ravi Ramamurti, the director at the Center for Emerging Markets at Northeastern University, contend the U.S. could slash its $3.3 trillion annual health-care tab by 30% to 40% over the next decade without making us sicker and without rationing care.
BRK.A

58
5 5G Stocks to Buy That Will Stream Higher Profits for Investors

2018-09-14 investorplace - 4
As telcos launch the first of the 5G networks, 5G stocks will become a focus. The technology will change wireless. How much speed it will add has become a point of controversy. Estimates from a few years ago predicted the improvement at 1,000 times 4G.
BRK.A S T TMUS AAPL CSCO NOK INTC

26
The Dow: A Risk Assessment (After GE, What's Next?)

2018-09-14 seekingalpha - 1
This report compares the Dow with the strongest financial statement trends with those with the weakest. GE is included as a point of reference.
BRK.A GEC GE TRV GNE DWDP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to BRK.A / Berkshire Hathaway, Inc. on message board site Silicon Investor.

BRK.A: Berkshire Hathaway Inc. BRK.A: Berkshire Hathaway Inc. BRK.A: Berkshire Hathaway Inc. Buy Berkshire instead of Vanguard Su0026P (BRKA) Buy Berkshire instead of Vanguard Su0026P (BRKA) Buy Berkshire instead of Vanguard Su0026P (BRKA)
Mr. Buffett: Who Really Cooks the Books Mr. Buffett: Who Really Cooks the Books Mr. Buffett: Who Really Cooks the Books Are there others like Buffett? (Berkshire Hathaway, BRKA) Are there others like Buffett? (Berkshire Hathaway, BRKA) Are there others like Buffett? (Berkshire Hathaway, BRKA)
CUSIP: 084670108